Moderna’s race to the vaccine
Listen now
Description
The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.   The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest. Read more here: Moderna’s Covid vaccine offers vindication of its unconventional approach Review clips: Yahoo Finance, CNBC   See acast.com/privacy for privacy and opt-out information.
More Episodes
The story of how a tiny, unknown hedge fund took on a giant of corporate America over climate change - and won. Charlie Penner of Engine No 1 talks about the very public proxy campaign he launched against Exxon Mobil, forcing the oil major to prepare for a future free of fossil fuels.   In the...
Published 10/06/21
Milton Friedman, the renowned American economist and spiritual mentor of many entrepreneurs, argued that the social responsibility of business was to increase profits. This has been the gospel since the early 1970s, but companies and investors are beginning to rethink the purpose of business. Has...
Published 09/23/21
When Tariq Fancy joined BlackRock as its first chief investment officer for sustainable investing in 2018, he was convinced that with companies around the world, including the world’s biggest asset manager, embracing environmental, social and governance (ESG) causes, the stage was set to reform...
Published 09/23/21